28/05/2023
Proof - Ivermectin CURES cancer
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug
Mandy Juarez et al. Cancer Chemother Pharmacol. 2020 Jun. https://pubmed.ncbi.nlm.nih.gov/32474842/
Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes
Na Li et al. EPMA J. 2020.
https://pubmed.ncbi.nlm.nih.gov/32549918/
Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth
Shican Zhou et al. Front Pharmacol. 2021.
https://pubmed.ncbi.nlm.nih.gov/34483925/
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
Mingyang Tang et al. Pharmacol Res. 2021 Jan.
https://pubmed.ncbi.nlm.nih.gov/32971268/
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
Dobrin Draganov et al. NPJ Breast Cancer. 2021.
https://pubmed.ncbi.nlm.nih.gov/33654071/
Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
Da Eun Lee et al. Front Pharmacol. 2022.
https://pubmed.ncbi.nlm.nih.gov/36091811/
Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage
Min Zhu et al. Biochem Biophys Res Commun. 2017.
https://pubmed.ncbi.nlm.nih.gov/28847725/
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma
Liang Chen et al. J Cell Mol Med. 2020 May.
https://pubmed.ncbi.nlm.nih.gov/32237037/
Topical ivermectin: a new successful treatment for scabies
J Victoria et al. Pediatr Dermatol. 2001 Jan-Feb. https://pubmed.ncbi.nlm.nih.gov/11207977/
Page 1 Abstract - [For this purpose, six complete families with active scabies, consisting of 12 adults and 20 children ranging in age from 1 to 10 years, were treated with 1% ivermectin in a solution of propylene glycol applied topically to the affected skin. The dose employed was 400 microg/kg, repeated once the following week. All patients were cured, tolerated the medication well, and there were no side effects or signs of recurrence 2, 4, or 6 weeks after therapy. In addition to its efficacy, easy administration, and lack of side effects, ivermectin is a low-cost medication.]
